Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.035 USD | -14.03% | +0.58% | -7.01% |
May. 13 | Terns Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 08 | Terns Pharmaceuticals, Inc. Announces Executive Changes | CI |
Business Summary
Number of employees: 66
Managers
Managers | Title | Age | Since |
---|---|---|---|
Amy Burroughs
CEO | Chief Executive Officer | 54 | Feb. 06 |
Erin Quirk
PSD | President | 53 | 18-12-31 |
Mark Vignola
DFI | Director of Finance/CFO | 47 | 20-08-10 |
Bryan Yoon
COO | Chief Operating Officer | 46 | 20-10-31 |
Chief Tech/Sci/R&D Officer | - | 22-01-05 | |
Justin Ng
IRC | Investor Relations Contact | - | - |
Corporate Officer/Principal | 44 | 23-04-30 | |
Melita Jung
PRN | Corporate Officer/Principal | 47 | Apr. 21 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
David Fellows
CHM | Chairman | 67 | 20-11-30 |
Jeffrey Kindler
BRD | Director/Board Member | 68 | 20-11-30 |
Carl Gordon
BRD | Director/Board Member | 59 | 18-09-30 |
Hong Bo Lu
BRD | Director/Board Member | 53 | 20-03-31 |
Director/Board Member | 44 | 22-07-25 | |
Jill Quigley
BRD | Director/Board Member | 49 | 20-11-30 |
Amy Burroughs
CEO | Chief Executive Officer | 54 | Feb. 06 |
Erin Quirk
PSD | President | 53 | 18-12-31 |
Ann Taylor
BRD | Director/Board Member | 67 | 21-09-27 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 64,677,145 | 63,525,621 ( 98.22 %) | 0 | 98.22 % |
Company contact information
Terns Pharmaceuticals, Inc.
1065 East Hillsdale Boulevard Suite 100
94404, Foster City
+650 525 5535
http://www.ternspharma.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.01% | 390M | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- TERN Stock
- Company Terns Pharmaceuticals, Inc.